HighTower Advisors
PTCT icon

HighTower Advisors’s PTC Therapeutics PTCT Stock Holding History

HighTower Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$480K Sell
5,888
-887
-13% -$64.1K ﹤0.01% 2784
2026
Q1 		$462K Buy
6,775
+3,556
+110% +$252K ﹤0.01% 2796
2025
Q4 		$245K Buy
+3,219
New +$234K ﹤0.01% 3211

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

HighTower Advisors's PTCT Position: Q2 2026 in Review

HighTower Advisors reduced its PTC Therapeutics (PTCT) stake by 13% in Q2 2026, selling an estimated $64.1K and leaving 5,888 shares worth $480K. The position accounts for ﹤0.01% of the portfolio, ranked #2784.

HighTower Advisors first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • HighTower Advisors held 5,888 shares of PTC Therapeutics worth $480K as of Q2 2026.
  • HighTower Advisors sold 887 PTC Therapeutics shares in Q2 2026, an estimated $64.1K.
  • PTC Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2784 holding.
  • HighTower Advisors first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.